V
Venkatraman E. Seshan
Researcher at Columbia University
Publications - 20
Citations - 2099
Venkatraman E. Seshan is an academic researcher from Columbia University. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 16, co-authored 20 publications receiving 1922 citations. Previous affiliations of Venkatraman E. Seshan include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Kerby Shedden,Jeremy M. G. Taylor,Steven A. Enkemann,Ming-Sound Tsao,Timothy J. Yeatman,William L. Gerald,Steven A. Eschrich,Igor Jurisica,Thomas J. Giordano,David E. Misek,Andrew C. Chang,Chang-Qi Zhu,Daniel Strumpf,Samir M. Hanash,Frances A. Shepherd,Keyue Ding,Lesley Seymour,Katsuhiko Naoki,Nathan A. Pennell,Barbara A. Weir,Roeland Verhaak,Christine Ladd-Acosta,Todd R. Golub,Michael Gruidl,Anupama Sharma,Janos Szoke,Maureen F. Zakowski,Valerie W. Rusch,Mark G. Kris,Agnes Viale,Noriko Motoi,William D. Travis,Barbara A. Conley,Venkatraman E. Seshan,Matthew Meyerson,Matthew Meyerson,Rork Kuick,Kevin K. Dobbin,Tracy Lively,James W. Jacobson,David G. Beer +40 more
TL;DR: A large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas, providing the largest available set of microarray data with extensive pathological and clinical annotation for lungAdenocARCinomas.
Journal ArticleDOI
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
TL;DR: It is shown that CRM-based methods are an improvement over the SM in terms of accuracy and optimal dose allocation in almost all cases, except when the true dose is among the lower levels.
Journal ArticleDOI
Global hypomethylation of genomic DNA in cancer-associated myofibroblasts
Le Jiang,Tamas A. Gonda,Mary V. Gamble,Martha Salas,Venkatraman E. Seshan,Shuiping Tu,William S. Twaddell,Péter Hegyi,György Lázár,Islay Steele,Andrea Varro,Timothy C. Wang,Benjamin Tycko +12 more
TL;DR: Evidence is shown for widespread hypomethylation in cancer-associated stromal myofibroblasts and its onset at the stage of noninvasive dysplastic lesions by immunohistochemistry for anti-5-methyl-C in a transgenic mouse model of multistage gastric carcinogenesis.
Journal ArticleDOI
Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers : Evidence for Distinct Tumor Behavior
Nisha Bansal,Thomas J. Herzog,Venkatraman E. Seshan,Peter B. Schiff,William M. Burke,Carmel J. Cohen,Jason D. Wright +6 more
TL;DR: It is demonstrated that uterine carcinosarcoma histology, advanced age, nonwhite race, and advanced stage were independent predictors of poor survival and may represent a distinct biologic entity.
Journal ArticleDOI
The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo
Wei Huang,Xin Li,Elizabeth A. Morris,Elizabeth A. Morris,Luminita A. Tudorica,Venkatraman E. Seshan,William D. Rooney,Ian J. Tagge,Ya Wang,Jingang Xu,Charles S. Springer +10 more
TL;DR: In analyses of routine DCE-MRI data from 22 patients with suspicious breast lesions initially ruled positive by institutional screening protocols, the SM Ktrans values for benign and malignant lesions exhibit considerable overlap, and the SM overestimates kep, particularly for the benign tumors.